Successful reintroduction and continuation of nivolumab in a patient with immune checkpoint inhibitor-induced bullous pemphigoid
| Autor: | Bruce Brockstein, Jason Waldinger, Nisha Desai, Maria L. Mihailescu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Immune checkpoint inhibitors Immune checkpoint inhibitor Immune system Immune-related adverse events Internal medicine polycyclic compounds medicine Adverse effect Melanoma RC254-282 General Environmental Science Advanced melanoma Bullous pemphigoid business.industry General Engineering Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Discontinuation Nivolumab General Earth and Planetary Sciences business hormones hormone substitutes and hormone antagonists |
| Zdroj: | Current Problems in Cancer: Case Reports, Vol 2, Iss, Pp 100031-(2020) |
| ISSN: | 2666-6219 |
| DOI: | 10.1016/j.cpccr.2020.100031 |
| Popis: | Many advanced cancers, such as melanoma, evade the immune system by exploiting negative feedback mechanisms. Immune checkpoint inhibitor (ICI) therapy dramatically enhances immune surveillance and has revolutionized treatment of advanced melanoma. However, ICI therapy is also associated with multiple cutaneous adverse events. We describe a patient treated with ICI, nivolumab, for stage 3D melanoma who developed bullous pemphigoid (BP). The patient achieved control of BP with discontinuation of ICI and a combination of topical and systemic steroids. Reintroduction of ICI therapy led to relapse of BP, which was successfully managed with an increase in systemic steroids allowing for continuation of ICI therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|